360Dx: C₂N Building Case for Alzheimer's Dx as Aducanumab Approval Promises to Impact Testing Space

Written By Joni Henderson

NEW YORK — With the recent publication of two peer-reviewed papers, Alzheimer's testing firm C₂N Diagnostics continues to build the case for its blood-based test.

Joni Henderson
Previous

Evaluate Vantage: Aduhelm approval amplifies amyloid assays
Next

BioWorld™ MedTech: Approval of aducanumab paves way for Alzheimer’s blood tests